FDA OKs Ixempra for advanced breast cancer

Oct 22, 2007

The U.S. Food and Drug Administration has approved Ixempra, a new anti-cancer treatment, for use in patients with metastatic or advanced breast cancer.

"This approval is important because it provides certain patients with a new chemotherapy option in instances where other drugs have failed," said Dr. Douglas Throckmorton, deputy director of the FDA's Center for Drug Evaluation and Research.

Ixempra (ixabepilone) was approved for use in combination with another cancer drug, capecitabine, in patients who no longer respond to two other chemotherapy treatments. The prior treatments included an anthracycline (such as doxorubicin or epirubicin) and a taxane (such as paclitaxel or docetaxel).

Ixempra, which is administered by intravenous infusion, was also approved for use alone in patients who no longer benefit from an anthracycline, a taxane and capecitabine.

The drug is distributed by the Bristol-Meyers Squibb Co. of Princeton, N.J.

Copyright 2007 by United Press International

Explore further: FDA panel rejects combination pain pill

add to favorites email to friend print save as pdf

Related Stories

Pilots' mental health a concern amid jet mystery

Mar 23, 2014

Reinforced doors with keypad entries. Body scanners and pat-downs. Elaborate crew maneuvers when a pilot has to use the restroom. All those tactics are designed to keep dangerous people out of the cockpit. ...

Plant scientists call for rethink of GM crop regulation

Mar 20, 2014

In a report to the Council for Science and Technology, which advises the Prime Minister on science policy, the scientists warn that unless GM crops are regulated at national, rather than at EU level, European ...

An end to animal testing for drug discovery?

Mar 18, 2014

As some countries and companies roll out new rules to limit animal testing in pharmaceutical products designed for people, scientists are stepping in with a new way to test therapeutic drug candidates and determine drug safety ...

Recommended for you

FDA proposes accelerated medical device approval plan

9 hours ago

(HealthDay)—The U.S. Food and Drug Administration has proposed a new program that would provide expedited access to high-risk medical devices intended for patients with serious conditions whose medical ...

Targeting drugs to reduce side effects

15 hours ago

(Medical Xpress)—Consider ice cream – the base of which is frozen cream. Ingredients are then added to make different flavours. All these flavours are distinctly different but are created from the same foundation.

User comments : 2

Adjust slider to filter visible comments by rank

Display comments: newest first

gdpawel
4 / 5 (2) Oct 26, 2007
As we enter the era of "personalized" medicine, it is time to take a fresh look at how we evaluate treatments for cancer patients. More emphasis should be put on matching treatment to the patient. Patients would certainly have a better chance of success had their cancer been chemo-sensitive rather than chemo-resistant, where it is more apparent that chemotherapy improves the survival of patient, and where identifying the most effective chemotherapy would be more likely to improve survival.

Ixempra would be the first in a new class of chemotherapy drugs called epothilones. The medicine, which is injected, works by inhibiting tubulin, a protein that acts like a scaffold inside cancer cells and is necessary for their proliferation. Known generically as ixabepilone, the drug tries to stymie tumors by keeping cancer cells from replicating successfully. Ixempra would be used alone or in combination with Xeloda, in patients who have failed two or three other chemo drugs.

The FDA's approval of a Bristol-Myers Squibb drug harkens back to the old-school for breast cancer patients who aren't responding to other treatments. For use by women who have tried - without success - prior types of treatment? Why not give them the "right" drug or combinations the "first" time around? Why not have a bio-marker to aid the physician in selecting an effective agent or combination of agents the first time around, to avoid exposing the patient to ineffective harmful drugs, reducing the cost and decreased quality of life associated with ineffective treatment? Everyone would agree that the earlier in the course of the disease that the most active treatment is given, the better the result for the patient.

The downside of Ixempra is that chemo that goes after dividing cells, also attacks healthy cells along with cancerous ones. Ixempra%u2019s side effects include fatigue, hair loss and anorexia. Patients may experience a decrease in red blood cells, muscle pain, joint pain, the feeling of pins and needles in their fingers and toes, and in severe cases, inability to use their hands and feet fully. Does Taxol sound familiar?

Scores of "new" cancer drug applications are for me-too drugs which might show only miniscule clinical improvement in trials, yet they somehow gain approval. So, for 1.6 months longer, patients can suffer from one or all of the above and still end up dead. Since they are marketed as if they were important new breakthroughs, they have very high prices. For most patients the total cost of a full course of Ixempra is expected to run from $18,440 to $23,050. Does Abraxane sound familiar?

There have been truly minuscule improvements as a result of adjuvant chemotherapy and the net benefit to the community of breast cancer patients in the real world isn't all that clear. And the criticism remains: All of the clinical trials resources have gone toward driving a square peg (one size fits all chemotherapy) into a round hole (notoriously heterogeneous disease).
Johnson_Chen
not rated yet Jan 16, 2008
HealthLat is inviting patients who take Ixempra to report their experiences with the new drug. Your experiences will help patients needed and make money for you.

You are also welcome to check how Ixempra has been used by other patients. It is free.

For details, please visit: http://www.healthlat.com

More news stories

Man among first in US to get 'bionic eye' (Update)

A degenerative eye disease slowly robbed Roger Pontz of his vision. Diagnosed with retinitis pigmentosa as a teenager, Pontz has been almost completely blind for years. Now, thanks to a high-tech procedure ...